TY - JOUR
T1 - Vinblastine, adriamycin, thiotepa, and halotestin (VATH). Therapy for advanced breast cancer refractory to prior chemotherapy
AU - Perloff, Marjorie
AU - Hart, Ronald D.
AU - Holland, James F.
PY - 1978/12
Y1 - 1978/12
N2 - Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combination of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 11.5 months, with 5/10 patients still responding at a mean follow‐up of 10 months. Only 2/10 responders have died with a mean follow‐up of 13.8 months. In contrast, 8/9 nonresponders have died (median survival 6.0 months). Response to therapy was neither in fluenced by site of disease, time interval from diagnosis to primary chemotherapy nor duration of response to primary chemotherapy. No patient was hospitalized because of drug induced toxicity. This combination of drugs is a tolerable effective regimen for patients relapsing after adjuvant chemotherapy or after primary combination chemotherapy for grossly metastatic disease. Cancer 42:2534–2537, 1978.
AB - Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combination of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 11.5 months, with 5/10 patients still responding at a mean follow‐up of 10 months. Only 2/10 responders have died with a mean follow‐up of 13.8 months. In contrast, 8/9 nonresponders have died (median survival 6.0 months). Response to therapy was neither in fluenced by site of disease, time interval from diagnosis to primary chemotherapy nor duration of response to primary chemotherapy. No patient was hospitalized because of drug induced toxicity. This combination of drugs is a tolerable effective regimen for patients relapsing after adjuvant chemotherapy or after primary combination chemotherapy for grossly metastatic disease. Cancer 42:2534–2537, 1978.
UR - http://www.scopus.com/inward/record.url?scp=0018248799&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197812)42:6<2534::AID-CNCR2820420605>3.0.CO;2-P
DO - 10.1002/1097-0142(197812)42:6<2534::AID-CNCR2820420605>3.0.CO;2-P
M3 - Article
C2 - 103610
AN - SCOPUS:0018248799
SN - 0008-543X
VL - 42
SP - 2534
EP - 2537
JO - Cancer
JF - Cancer
IS - 6
ER -